Anticancer Research · 2018 · 82 citations · 23 references
MedicineImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyCancer ImmunotherapyCancer Survival AnalysisColorectal CancerImmune Checkpoint InhibitorsImmune Checkpoint RegulationRegulatory T CellsColorectal Cancer PrognosisDisease-free Survival AnalysisPrognostic BiomarkersPrognostic Factors AnalysisProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 UpregulationSurvival Rates
BACKGROUND/AIM: Programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1(PD-L1) axis is associated with immune tolerance via inhibition of T cell activation. The aim of this study was to clarify the significance of PD-1 and PD-L1 expressions and analyze the relationships between PD-1, PD-L1, transforming growth factor-β (TGF-β) and Forkhead box P3 (Foxp3) expressions in colorectal cancer (CRC). PATIENTS AND METHODS: A total of 116 patients who underwent curative colectomy for stage II/III CRC were included in the study. PD-1, PD-L1, TGF-β, and Foxp3 expressions were examined by immunohistochemistry and related to prognostic factors by Kaplan-Meier. RESULTS: PD-1 expression was correlated with PD-L1, TGF-β, and Foxp3 expressions. Overall survival rates were significantly poorer in the PD-1 and PD-L1-positive groups. Multivariate analysis showed that PD-L1-positive is an independent risk factor. Disease-free survival (DFS) was tended in the PD-L1-positive group. The group with double-positive expression had significantly poorer prognosis. CONCLUSION: PD-1 and PD-L1 expressions were associated with a poor prognosis and correlated with TGF-β and Foxp3 expressions in patients with CRC.
23
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +12